Short Duration Treatment of Non-severe Community Acquired Pneumonia (PTC)
A Non-Inferiority, Multicentered, Controlled, Randomized, Double Blinded Study Investigating the Antibiotic Treatment Duration (3-day Versus 8-day) for Subjects Admitted to Emergency Services With Acute Non-severe Community Acquired Pneumonia (CAP)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Anne-Claude CREMIEUX, PH
- Phone Number: 0033147107730
- Email: anne-claude.cremieux@rpc.aphp.fr
Study Contact Backup
- Name: Aurélien DINH, Dr
- Email: aurelien.dinh@rpc.aphp.fr
Study Locations
-
-
-
Argenteuil, France, 95107
- Active, not recruiting
- CH Argenteuil
-
Boulogne-Billancourt, France, 92100
- Recruiting
- CHU Ambroise Paré
-
Sub-Investigator:
- Aurelien DINH, Dr
-
Clichy, France, 92110
- Recruiting
- CH Beaujon
-
Principal Investigator:
- Victoire De Lastours, Dr
-
Creteil, France, 94000
- Recruiting
- Chi Creteil
-
Principal Investigator:
- Valerie GARRAIT, Dr
-
Garches, France, 92380
- Recruiting
- Central Hospital Raymon Poincaré
-
Principal Investigator:
- Benjamin DAVIDO, PH
-
La Tronche, France, 38700
- Recruiting
- CHU de GRENOBLE
-
Principal Investigator:
- Jean-Paul STAHL, Dr
-
Le Chesnay, France, 78150
- Active, not recruiting
- CH Versailles
-
Le Kremlin Bicètre, France, 94275
- Recruiting
- Ch Bicetre
-
Principal Investigator:
- Benjamin WIPLOSZ, Pr
-
Melun, France, 77000
- Recruiting
- Melun Hospital
-
Principal Investigator:
- Sylvain DIAMANTIS, Dr
-
Metz-Tessy, France, 74370
- Active, not recruiting
- CH d'Annecy Genevois
-
Paris, France, 75010
- Recruiting
- CH Lariboisière
-
Principal Investigator:
- Véronique DELCEY, Dr
-
Paris, France, 75012
- Active, not recruiting
- Chu Saint Antoine
-
Paris, France, 75014
- Withdrawn
- CHU Cochin
-
Paris, France, 75018
- Withdrawn
- CHU Bichat
-
Paris, France, 75020
- Not yet recruiting
- CH Tenon
-
Principal Investigator:
- Gilles Pialoux, Dr
-
Pontoise, France, 95300
- Active, not recruiting
- CH Pontoise
-
Rennes, France, 35033
- Withdrawn
- Chu Rennes Pontchaillou
-
Rouen, France, 76031
- Recruiting
- CHU Rouen
-
Principal Investigator:
- Daniel BENHAMOU, Dr
-
Saint Denis, France, 93205
- Active, not recruiting
- CH Saint Denis
-
Suresnes, France, 92151
- Recruiting
- Foch Hospital
-
Principal Investigator:
- Jean-Emmanuel Kahn, Dr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject must be 18 years old or over.
- admitted three days before for Community Acquired Pneumonia (CAP) defined by at least one clinical sign of pneumonia (dyspnea, cough, mucopurulent sputum, crackling sound on lungs) associated with a temperature >38°C on admission, and a new infiltrate consistent with pneumonia on chest x-ray, who responded favorably to 3 days of treatment with β-lactams (third generation injectable cephalosporin or amoxicillin-clavulanate)
- able to take oral medication.
- has given its informed consent.
Exclusion Criteria:
- Creatinin < 30ml/min
- History of jaundice / hepatic impairment associated with amoxicillin / clavulanic acid
- History of hypersensitivity to beta-lactam
- Presence of complications or severity of pneumonia (abscess , significant pleural effusion, severe chronic respiratory failure , septic shock, respiratory condition requiring the passage resuscitation).
- Known immunocompromised terrain ( asplenia , neutropenia, agammaglobulinemia , immunosuppressants, graft corticosteroids , myeloma , lymphoma, known HIV , sickle cell anemia , CHILD C cirrhosis).
- Antibiotic treatment exceeding 24 hours prior admission.
- Suspected atypical bacteria requiring combined antibiotics therapy .(Subjects who received a single dose of macrolides or fluoroquinolones emergency will not be excluded) .
- Legionella suspected on clinical, biological and radiological criteria .
- Subjects with clinical or epidemiological environment leading to suspect a healthcare-associated pneumonia with antibiotic resistant pathogen.
- Suspicion of pneumonia by aspiration.
- Intercurrent infection requiring antibiotic treatment.
- Pregnant women .
- Breastfeeding .
- Allergy to antibiotics in use.
- Life expectancy <1 month .
- Subject without health insurance.
- Subjects without home adress
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Amoxicillin/Clavulanic acid treatment
after 3 day treatment of β-lactams, the subjects receive 5-day treatment of Amoxicillin/clavulanic acid.
Chest X-ray performed at admission and Day 30 and replapses.
'blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
|
at Day 0, Day 30 and relapse
2 tablets 3 times a day for 5 days from Day 3
administered from Day 0 to Day 3
|
|
Placebo Comparator: placebo treatment
after 3-day treatment of β-lactams, the subjects receive 5-day treatment of placebo.
Chest X-ray performed at admission and Day 30 and replapse.
blood sampling /Cell Counts/CRP/Biochemistry' performed at Day 0, Day 30 and relapse
|
at Day 0, Day 30 and relapse
administered from Day 0 to Day 3
2 tablets 3 times a day for 5 days from Day 3
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clinical evaluation at Day 15
Time Frame: Day 15
|
Clinical evaluation at Day 15 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and confirmation that no additionnal antibiotic treatment was required from Day 8
|
Day 15
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
clinical evaluation at Day 30
Time Frame: Day 30
|
Clinical evaluation at Day 30 composed of the composite measure of the Clinical examination for clinical symptoms of CAP, recording of the body temperature and Evaluation of replapse or aggravation of pneumonia or any other respiratory infections in subjects considered cured at Day 15.
|
Day 30
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
mortality all causes at Day 30
Time Frame: Day 30
|
Day 30
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anne-Claude CREMIEUX, Pr, Central Hospital Raymon Poincaré
- Principal Investigator: Marie Christine DOMBRET, Dr, CHU Bichat
- Principal Investigator: Matthieu GROH, Dr, CHU Cochin
- Principal Investigator: Elizabeth ROUVEIX, Pr, CHU Ambroise Paré
- Principal Investigator: Pascale LONGUET, Dr, CH Argenteuil
- Principal Investigator: Daniel BENHAMOU, Dr, CHU Rouen
- Principal Investigator: Sylvain DIAMANTIS, Dr, Melun Hospital
- Principal Investigator: Jean-Emmanuel Kahn, Dr, Foch Hospital
- Principal Investigator: Jean-François BOITIAUX, Dr, Pontoise Hospital
- Principal Investigator: Jean-Pierre BEDOS, Pr, Central Hospital of Versailles
- Principal Investigator: Jêrome PACANOWSKI, Dr, CHU Saint Antoine (Paris)
- Principal Investigator: Valérie GARRAIT, Dr, Chi Creteil
- Principal Investigator: Elena FOIS, Dr, CH Saint Denis
- Principal Investigator: Benjamin WYPLOSZ, Pr, Ch Bicetre
- Principal Investigator: Véronique DELCEY, Dr, CH Lariboisière
- Principal Investigator: Gilles PIALOUX, Dr, CH Tenon
- Principal Investigator: Matthieu REVEST, Dr, Chu Rennes Pontchaillou
- Principal Investigator: Jean Paul STAHL, Dr, University Hospital, Grenoble
- Principal Investigator: Virginie VITRAT, Dr, CH Annecy Genevois
- Principal Investigator: Victoire De Lastours, Dr, CH Beaujon
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PHRC-12-202.0496 - PTC
- 2013-000265-36 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.